STEAP1B

Across TCGA pan-cancer cohorts, STEAP1B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STEAP1B data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher STEAP1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated STEAP1B expression acts as an unfavorable survival marker.

SARC, LIHC, and BLCA are the cancer types where STEAP1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
LIHC	OS	Median	All	0.094	0.783	<.001	12	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →
LUAD	OS	Median	All	0.323	0.834	.003	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STEAP1B–SARC (DFS)

Open the SARC breakdown →